<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Consumption of sugar-sweetened beverages (SSBs), which include soft drinks, fruit drinks, iced tea, and energy and vitamin water drinks has risen across the globe </plain></SENT>
<SENT sid="1" pm="."><plain>Regular consumption of SSBs has been associated with <z:mp ids='MP_0005456'>weight gain</z:mp> and risk of overweight and <z:hpo ids='HP_0001513'>obesity</z:hpo>, but the role of SSBs in the development of related <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0025517" disease_type="Disease or Syndrome" abbrv="">metabolic diseases</z:e>, such as <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, has not been quantitatively reviewed </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: We searched the MEDLINE database up to May 2010 for prospective cohort studies of SSB intake and risk of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>We identified 11 studies (three for <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and eight for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>) for inclusion in a random-effects meta-analysis comparing SSB intake in the highest to lowest quantiles in relation to risk of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Based on data from these studies, including 310,819 participants and 15,043 cases of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, individuals in the highest quantile of SSB intake (most often 1-2 servings/day) had a 26% greater risk of developing type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> than those in the lowest quantile (none or &lt;1 serving/month) (relative risk [RR] 1.26 [95% CI 1.12-1.41]) </plain></SENT>
<SENT sid="5" pm="."><plain>Among studies evaluating <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>, including 19,431 participants and 5,803 cases, the pooled RR was 1.20 [1.02-1.42] </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: In addition to <z:mp ids='MP_0005456'>weight gain</z:mp>, higher consumption of SSBs is associated with development of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>These data provide empirical evidence that intake of SSBs should be limited to reduce <z:hpo ids='HP_0001513'>obesity</z:hpo>-related risk of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0025517" disease_type="Disease or Syndrome" abbrv="">metabolic diseases</z:e> </plain></SENT>
</text></document>